Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C

Hepatology Research

Volumn 41, Issue 2, 2011, Pages 118-125

  Aoki, Yo hei ^a   Ohkoshi, Shogo ^a   Yamagiwa, Satoshi ^a   Yano, Masahiko ^a   Takahashi, Hiromichi ^a   Waguri, Nobuo ^b   Igarashi, Kentaro ^b   Sugitani, Soh ichi ^c   Takahashi, Toru ^d   Ishikawa, Toru ^e   Kamimura, Tomoteru ^e   Wakabayashi, Hiroto ^f   Watanabe, Toshiaki ^g   Matsuda, Yasunobu ^a   Nomoto, Minoru ^a   Aoyagi, Yutaka ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b National Hospital Organization   (Japan)

^c Tachikawa General Hospital   (Japan)

^d NAGAOKA RED CROSS HOSPITAL   (Japan)

^e Sai sei kai Second Hospital   (Japan)

^f Takeda General Hospital   (Japan)

^g Watanabe Clinic   (Japan)

Author keywords

Abnormal ALT values; BMI; Drug involvement; Pegylated interferon 2b; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CLEARANCE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79251507671     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00749.x     Document Type: Article

References (23)

1. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006; 41: 17-27.
2. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 2005; 10 (Suppl 2): S141-3.
3. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 610-22.
4. Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007; 14 (Suppl 1): 82-8.
5. Cervoni J-P, Degos F, Marcellin P, Erlinger S. Acute hepatitis induced by interferon, associated with viral clearance, in chronic viral hepatitis. J Hepatol 1997; 27: 1113-16.
6. Kogure T, Ueno Y, Fukushima K etal. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol 2007; 13: 4394-7.
7. Sezaki H, Arase Y, Tsubota A etal. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003; 38: 493-500.
8. Dusheiko G. Side effects of alpha interferon in chronic hepatitis. Hepatology 1997; 26 (Suppl 1): 112S-21S.
9. Thurairajah PH, Thorburn D, Hubsher S etal. Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Phamacol Ther 2007; 25: 1293-300.
10. Basso M, Edoardo G, Torre F, Blanchi S, Savarino V, Picciotto A. Elevations in alanine aminotransferase levels late in the course of anti-viral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. Hepatology 2009; 49: 1442-8.
11. Kleiner DE, Brunt EM, Natta MV etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
12. Hung CH, Lee CM, Lu SN etal. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroentarol Hepatol 2002; 17: 1307-11.
13. Zeuzem S, Feinman SV, Rasenack J etal. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
14. Bressler BL, Guindi M, Tomlinson G, Heathcoate J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
15. Fujiwara Y, Kiura K, Hotta K, Tabata M, Takikawa N, Tanimoto M. Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. Lung Cancer 2007; 55: 343-8.
16. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-7.
17. Lind MJ, Margison JM, Cerny T, Thacher N, Wilkinson PM. Prolongation of isosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 1989; 25: 139-42.
18. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Phamacokinet 2000; 39: 215-31.
19. Koike K, Moriya K. Metabolic aspects of hepatitis C virus infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005; 40: 329-36.
20. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 2127-33.
21. Scheuer JP, Lefkowitch JH. Liver Biopsy Interpretation, 7th edn. Burlington: Elsevier Saunders, 2006; 125-44.
22. Nagashima M, Kudo M, Chung H etal. Elevated serum ALT levels during pegylated interferon monotherapy may be caused by iron overload. Intervirology 2008; 51 (Suppl 1): S76-85.
23. Webster R, Didier E, Harris P etal. Pegylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007; 35: 9-16.